548 / 923
HDR MONOTHERAPY
•
High rates of biochemical control in early years
•
Optimal indication yet to be defined:
?intermediate/high risk…?low risk
•
Acute toxicity short-lived cf LDR BT
•
Late toxicity profile favourable with low rates
of late urinary and erectile dysfunction